NEW YORK, July 2 /CNW/ -- Pulmo BioTech Inc. (OTC Bulletin Board:
PLMO.OB) has announced the possibility of a new application for its PulmoBind
Molecular Imaging technology.
The PulmoBind product candidates being developed by Pulmo BioTech
subsidiary PulmoScience are designed to allow the imaging of the vascular
system of the lungs by a diagnostic clinician and thus enable the diagnosis of
Pulmonary Embolism, Pulmonary Hypertension and Lung Inflammatory conditions.
The way in which this will be achieved is to tag a molecule which
preferentially bonds to the inner walls of the capillaries in the lungs with a
gamma emitting radionuclide so that the position of the molecules can be seen
using a standard Gamma Camera, which is available in all hospitals with a
Nuclear Medicine department.
PulmoScience is now pleased to announce that it has had preliminary
success with also tagging its Molecular Imaging candidates with a magnetic
resonance contrast agent. If this work is successful it will allow the medical
community to also use MRI scanners for lung vascular studies and potentially
increase the addressable market for PulmoBind.
About Pulmo BioTech Inc.
Pulmo BioTech Inc. specializes in the development and marketing of
medical technology and research. Our proven strengths combine extensive
commercial experience and academic credentials. The principal staff members
are acknowledged experts in their specialized fields, and work with a broad
range of investment institutions. Pulmo BioTech's mission is to utilize
scientific imagination and drive, together with managerial and financial
acumen, to bring innovative and profitable products to the marketplace to the
benefit of all stock holders.
About PulmoScience Inc.
PulmoScience Inc. was established in 2006, and is currently developing a
non-invasive Molecular Imaging technique for the diagnosis of Pulmonary
Embolism, Pulmonary Hypertension and Lung Inflammatory diseases under the
trade name PulmoBind.
The company was conceived within the Montreal Heart Institute "MHI" (a
world renowned hospital and educational facility). Jointly owned by MHI
subsidiary Innovacor as the technical and operational partner, Dr Jocelyn
Dupuis (the scientific director and originator of the PulmoBind Molecular
Imaging technology), and by Pulmo BioTech Inc. as the funding partner,
PulmoScience Inc. aims to develop this unique and exciting technology, to fund
necessary trials, and to bring the products to market.
PulmoScience believes that the market for its product candidates is worth
in excess of $500 million per annum and that, provided Regulatory Approval is
achieved, the safety and efficacy of its products could allow it to dominate
that market.
About PulmoBind
PulmoBind uses an intravenously delivered radionuclide tagged molecule
which specifically bonds to the inner walls of the circulatory system in the
lungs, and by the use of an external Gamma Camera allows an image of the
integrity of the blood vessels throughout the lungs to be seen by a diagnostic
clinician. PulmoScience is currently undertaking Regulatory Approval for Phase
I Human Trials, and while subsequent results from additional tests might not
corroborate the current results, PulmoScience believes that PulmoBind has the
potential to dominate the market for the diagnosis of Pulmonary Embolism. In
particular, this belief is driven by PulmoScience's expectations of the
improved safety and efficacy that PulmoBind will offer when compared to the
current incumbent nuclear medicine based technology for the diagnosis of
Pulmonary Embolism. In addition, early indications are that PulmoBind could
be highly effective in the early stage diagnosis of Pulmonary Hypertension, a
condition for which there is no current front line diagnostic test. The
addressable market for the product candidates being developed by PulmoScience
is believed by the company to be worth in excess of $500 million per annum.
Forward-Looking Statements
Forward-looking statements contained in this and other written and oral
reports are made based on known events and circumstances at the time of
release, and as such, are subject in the future to unforeseen uncertainties
and risks. All statements regarding future performance, earnings projections,
regulatory approval, events or developments are forward-looking statements. It
is possible that the future performance and of the company may differ
materially from current expectations, depending on economic conditions and the
uncertainty of regulatory approval. A change in economic conditions may have a
particularly volatile effect on results. Among the other factors which may
affect future performance are: competitive market conditions and resulting
effects on sales and pricing; increases in raw-material costs that cannot be
recovered in product pricing; and global economic factors, including
difficulties entering new markets and general economic conditions such as
inflation, interest rates and credit availability. The company makes these
statements as of the date of this disclosure, and undertakes no obligation to
update them.